Engineered Expression of Broadly Neutralizing Antibodies Against Human Immunodeficiency Virus

Area of Science:

• Immunology
• Virology
• Vaccinology

Background:

• Current human immunodeficiency virus (HIV) vaccines and treatments have limitations.
• The RV144 vaccination trial identified challenges in developing effective HIV vaccines.

Purpose of the Study:

• To review recent advancements in HIV prevention and treatment strategies.
• To explore the potential of broadly neutralizing antibodies (bNAbs) in overcoming current HIV intervention shortcomings.

Main Methods:

• Review of research on engineered expression of bNAbs against HIV-1.
• Analysis of sequential immunogens for B cell activation to produce bNAbs.
• Evaluation of passive administration of potent bNAbs.
• Assessment of gene transfer using adeno-associated viral vectors for bNAb delivery.

Main Results:

• Engineered expression of bNAbs shows potential to address limitations in HIV vaccine and treatment development.
• Sequential immunogens can activate B cells to produce bNAbs.
• Passive administration and gene transfer are viable methods for delivering bNAbs.

Conclusions:

• Broadly neutralizing antibodies (bNAbs) represent a promising avenue for novel HIV vaccines and treatments.
• Targeted strategies involving bNAbs could overcome existing challenges in HIV intervention.
• Further research into bNAb-based therapies is warranted for effective HIV control.